此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints (RESYNC-PACE)

2026年7月8日 更新者:Peter Ezer、University of Pecs

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints RESYNC-PACE

The goal of this observational study is to evaluate the long-term clinical outcomes of physiologic cardiac resynchronization therapy (CRT) using conduction system pacing strategies compared with conventional biventricular CRT in patients with heart failure with reduced ejection fraction (HFrEF) and electrical dyssynchrony.

The main questions it aims to answer are:

  • Does physiologic CRT (including left bundle branch area pacing [LBBAP] and LBBAP-optimized CRT) reduce the combined risk of all-cause mortality and heart failure hospitalization compared with conventional biventricular CRT?
  • Does physiologic CRT improve cardiac function and reverse ventricular remodeling more effectively than conventional CRT?

Participants receiving physiologic CRT as part of routine clinical care will undergo standard follow-up evaluations, including electrocardiography, echocardiography, laboratory testing, and device interrogation. Clinical outcomes will be collected prospectively for 24 months and compared with a historical cohort of patients treated with conventional biventricular CRT.

The study will assess clinical outcomes, echocardiographic response, electrical resynchronization parameters, and device-related safety in a real-world heart failure population.

研究概览

详细说明

Background

Heart failure with reduced ejection fraction (HFrEF) is associated with substantial morbidity, mortality, and healthcare utilization despite continuous advances in guideline-directed medical therapy. Cardiac resynchronization therapy (CRT) has become an established treatment for patients with symptomatic HFrEF and electrical dyssynchrony. Conventional biventricular pacing improves ventricular synchrony and clinical outcomes; however, approximately one-third of treated patients do not achieve a satisfactory response.

Conduction system pacing (CSP), particularly left bundle branch area pacing (LBBAP), has emerged as a physiological pacing strategy capable of directly engaging the native His-Purkinje conduction system. Compared with conventional biventricular pacing, CSP may produce more physiological ventricular activation, narrower paced QRS complexes, improved electrical synchrony, and greater reverse ventricular remodeling. Nevertheless, evidence regarding its long-term effectiveness in routine clinical practice remains limited, particularly in heterogeneous populations with different conduction abnormalities.

Study Rationale

The RESYNC-PACE study was designed to evaluate the effectiveness of individualized physiologic cardiac resynchronization strategies in a real-world population of patients with HFrEF requiring CRT.

The study investigates two complementary physiologic CRT approaches according to the underlying conduction disturbance. In patients with typical left bundle branch block (LBBB), left ventricular lead implantation is guided by the qLV ratio to achieve optimal electrical resynchronization through individualized coronary sinus lead positioning. In patients with intraventricular conduction delay (IVCD), a conduction system pacing strategy is applied using left bundle branch area pacing. When conduction system pacing alone results in incomplete electrical correction, defined by a paced QRS duration greater than 130 ms, an additional coronary sinus left ventricular lead is implanted to establish Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT).

This individualized treatment algorithm reflects contemporary physiological concepts of ventricular resynchronization rather than a single implantation strategy and represents the principal scientific concept investigated in the study.

Scientific Objectives

The study aims to determine whether physiologic CRT strategies provide superior long-term clinical outcomes compared with conventional biventricular CRT when implemented in routine clinical practice.

In addition to evaluating clinical outcomes, the study investigates the relationship between electrical resynchronization, ventricular reverse remodeling, myocardial scar characteristics assessed by cardiac magnetic resonance imaging, and long-term prognosis. Particular emphasis is placed on identifying imaging-, electrocardiographic-, and device-derived predictors of CRT response that may facilitate patient selection and optimization of resynchronization therapy.

Study Methodology

RESYNC-PACE is a single-center, ambispective observational cohort study performed at the University of Pécs Clinical Centre Heart Institute. Consecutive patients undergoing physiologic CRT constitute the prospective cohort, while a historical cohort of patients treated with conventional biventricular CRT serves as the comparator.

All therapeutic procedures are performed as part of routine clinical care using commercially available CE-marked cardiac implantable electronic devices according to their approved indications and current international guideline recommendations. The study does not introduce experimental devices or procedures beyond standard clinical practice but prospectively evaluates the clinical performance of an individualized physiological CRT algorithm.

The comprehensive study database integrates demographic, clinical, electrocardiographic, echocardiographic, cardiac magnetic resonance imaging, procedural, device-derived, and long-term follow-up data. This integrated approach enables detailed evaluation of the mechanisms underlying CRT response and supports the development of patient-specific resynchronization strategies.

Expected Clinical Significance

The RESYNC-PACE study is expected to generate real-world evidence regarding the effectiveness of conduction system pacing-guided CRT strategies and individualized resynchronization algorithms. The findings may improve patient selection, optimize implantation strategies for different conduction disorders, and contribute to the growing evidence supporting physiologic cardiac resynchronization therapy in patients with heart failure.

研究类型

观察性的

注册 (估计的)

50

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Peter Ezer MD PhD, assistant professor
  • 电话号码:+36305468840
  • 邮箱:ezerpeti@gmail.com

学习地点

    • Baranya
      • Pécs、Baranya、匈牙利、7621
        • Heart Institute , University of Pécs

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population consists of adult patients with heart failure with reduced ejection fraction (HFrEF) who are treated at the University of Pécs Clinical Centre Heart Institute and meet contemporary guideline indications for cardiac resynchronization therapy (CRT). Eligible participants have symptomatic heart failure despite guideline-directed medical therapy, left ventricular systolic dysfunction, and evidence of electrical dyssynchrony manifested by left bundle branch block (LBBB) or intraventricular conduction delay (IVCD). The prospective cohort includes patients undergoing conduction system pacing-based CRT as part of routine clinical care, while the historical control cohort includes patients previously treated with conventional biventricular CRT at the same institution. The study population represents a real-world heart failure population routinely referred for CRT implantation in tertiary cardiovascular care.

描述

Inclusion Criteria:

  • Age ≥18 years.
  • Symptomatic heart failure despite guideline-directed medical therapy.
  • Left ventricular ejection fraction (LVEF) ≤40%.
  • Indication for cardiac resynchronization therapy according to contemporary ESC guideline recommendations.
  • QRS duration ≥150 ms with either:

Left bundle branch block (LBBB), or Intraventricular conduction delay (IVCD).

  • Planned implantation of a CRT system
  • Ability to provide written informed consent
  • Expected survival greater than 24 months.

Exclusion Criteria:

  • Age <18 years and Age 100 < years
  • Pregnancy or breastfeeding.
  • Inability or unwillingness to provide informed consent.
  • Life expectancy <12 months due to non-cardiac comorbidities.
  • Active systemic infection or infection involving a cardiac implantable electronic device.
  • Reversible causes of heart failure expected to improve without CRT.
  • Participation in another interventional clinical trial that may affect study outcomes.
  • Inability to comply with follow-up requirements.
  • Missing essential baseline or follow-up data (retrospective cohort).
  • Any condition that, in the opinion of the investigators, would make participation inappropriate or interfere with study assessments.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Left bundle branch block patients

LBBB Cohort (qLV-guided Cardiac Resynchronization Therapy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and complete left bundle branch block (LBBB) according to contemporary guideline criteria. Cardiac resynchronization therapy is performed using a personalized implantation strategy guided by the qLV ratio, defined as the interval between QRS onset and local left ventricular activation divided by the intrinsic QRS duration. The left ventricular lead is positioned at the site with the longest achievable electrical delay to maximize resynchronization benefit. Patients receive either conventional biventricular CRT or LOT- CRT according to clinical decision-making and anatomical feasibility. The cohort is followed longitudinally to evaluate the relationship between qLV-guided lead placement, electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
其他名称:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.
Intraventricular conduction delay patients

IVCD Cohort (Conduction System Pacing-Guided Resynchronization Strategy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and intraventricular conduction delay (IVCD) without typical left bundle branch block morphology. The resynchronization strategy is guided by the degree of electrical correction achieved with conduction system pacing. During implantation, left bundle branch area pacing (LBBAP) is attempted and paced QRS duration is assessed. If conduction system pacing alone results in a paced QRS duration greater than 130 ms, a Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT) system is implanted by adding a left ventricular lead to further improve ventricular synchrony. The cohort is followed longitudinally to evaluate the association between electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
其他名称:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Composite of All-Cause Mortality and Heart Failure Hospitalization
大体时间:24 months
Time to first occurrence of the composite endpoint of all-cause mortality or hospitalization due to worsening heart failure during the 24-month follow-up period.
24 months

次要结果测量

结果测量
措施说明
大体时间
Change in Left Ventricular Ejection Fraction (LVEF)
大体时间:Baseline to 24 months

Change in left ventricular ejection fraction measured by transthoracic echocardiography between baseline and 24-month follow-up.

Ejection fraction is measured in percentage (%). Improvement in ejection fraction is detected as increase in percentage-value.

Baseline to 24 months
Change in Left Ventricular End-Systolic Volume ( LV ESV)
大体时间:Baseline to 24 months

Change in left ventricular end-systolic volumen measured by echocardiography between baseline and 24-month follow-up.

Left ventricular end-systolic volume in measured in mililiters ( ml) , decrease in LV ESV is a sign of clinical response on therapy.

Baseline to 24 months
Change in paced QRS Duration
大体时间:Baseline to 24 months

Reduction in QRS duration following cardiac resynchronization therapy compared with baseline electrocardiographic measurements.

Paced QRS duration is measured in miliseconds (ms). Decrease in paced QRS duration compared to preoperative QRS duration is marked as a good signal in cardiac resynchronization therapy.

Baseline to 24 months
New York Heart Association Heart Failure Functional Status
大体时间:Baseline to 24 months

Change in New York Heart Association (NYHA) functional class from baseline to follow-up. Stage I-IV.

NYHA improvement is detected as decrease in NYHA stage grade.

Baseline to 24 months

其他结果措施

结果测量
措施说明
大体时间
Device-Related and Procedure-Related Complications
大体时间:24 months
Incidence of device-related and procedure-related adverse events, including lead dislodgement, infection, pneumothorax, pocket hematoma, and system revision.
24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月29日

初级完成 (估计的)

2030年6月29日

研究完成 (估计的)

2031年6月29日

研究注册日期

首次提交

2026年6月28日

首先提交符合 QC 标准的

2026年6月28日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年7月10日

上次提交的符合 QC 标准的更新

2026年7月8日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • FF107 RESYNC-PACE ver1.0
  • Biotronik Research Grant FF107 (其他赠款/资助编号:BIOTRONIK SE & Co. KG Woermannkehre 1 12359 Berlin)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

ndividual participant data will be shared only in a de-identified form and in accordance with applicable data protection regulations, institutional policies, and informed consent provisions. Data sharing may be limited where participant privacy, ethical considerations, or legal requirements prevent full disclosure of individual-level data.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅